Previous 10 | Next 10 |
WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2023 and ...
2024-01-22 17:55:10 ET More on Aclaris Therapeutics Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report Aclaris spikes after leadership change, strategic review Aclaris draws second downgrade despite Phase 2 win for eczema therapy Seeking Al...
2024-01-22 08:37:55 ET Rail Vision ( RVSN ) +96% Successfully Secures Approval and Certifications and for EU Railway Standards. Nustar Energy ( NS ) +23% to buy NuStar in all-stock deal valued at $7.3B. MSP Recovery ( LIFW ) +23% . North...
2024-01-16 08:58:06 ET More on Aclaris Therapeutics Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report Aclaris draws second downgrade despite Phase 2 win for eczema therapy Aclaris downgraded at Jefferies despite mid-stage win for eczema therapy ...
- Douglas Manion, M.D. to step down as Chief Executive Officer, President and Member of Board of Directors - - Dr. Neal Walker, Current Chairman and Co-founder, Appointed as Interim Chief Executive Officer - WAYNE, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. ...
2024-01-11 13:30:02 ET Stifel Nicolaus analyst issues BUY recommendation for ACRS on January 11, 2024 02:00PM ET. The previous analyst recommendation was Buy. ACRS was trading at $0.9751 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...
2024-01-11 07:53:52 ET More on Aclaris Therapeutics Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report Aclaris downgraded at Jefferies despite mid-stage win for eczema therapy Aclaris posts topline data from mid-stage trial for eczema therapy ...
2024-01-10 15:09:26 ET More on Aclaris Therapeutics Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report Aclaris posts topline data from mid-stage trial for eczema therapy Aclaris to slash 46% of workforce as it reprioritizes drug programs Se...
2024-01-10 10:00:10 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming Covid-vaccine makers top laggard list, LLY and WST top gainers list Healthcare and utilities could perform better in 2024 - analyst For further details see: See...
2024-01-10 07:53:46 ET More on Aclaris Therapeutics Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report Aclaris to slash 46% of workforce as it reprioritizes drug programs Aclaris Therapeutics announces patent license agreement with Sun Pharma for a...
News, Short Squeeze, Breakout and More Instantly...
Aclaris Therapeutics Inc. Company Name:
ACRS Stock Symbol:
NASDAQ Market:
Aclaris Therapeutics Inc. Website:
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will part...
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidat...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...